Product Center
Launch Meeting of Post-Marketing Safety Evaluation Study for Tetravalent Influenza Virus Subunit Vaccine Concludes Successfully
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25
- Views:
(Summary description)Recently, the kickoff meeting for Ab&B Bio-Tech Co., Ltd. JS's post-marketing safety evaluation study of its tetravalent influenza virus subunit vaccine was successfully held in Lanzhou, Gansu Province.
Launch Meeting of Post-Marketing Safety Evaluation Study for Tetravalent Influenza Virus Subunit Vaccine Concludes Successfully
(Summary description)Recently, the kickoff meeting for Ab&B Bio-Tech Co., Ltd. JS's post-marketing safety evaluation study of its tetravalent influenza virus subunit vaccine was successfully held in Lanzhou, Gansu Province.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25 14:16
- Views:
Recently, the kickoff meeting for Ab&B Bio-Tech Co., Ltd. JS's post-marketing safety evaluation study of its tetravalent influenza virus subunit vaccine was successfully held in Lanzhou, Gansu Province.
This multicenter study is led by the Jiangsu Provincial Center for Disease Control and Prevention, under the guidance of the Jiangsu Provincial Center for Adverse Drug Reaction Monitoring, and jointly conducted by six provincial CDCs, aiming to evaluate the safety profile of the tetravalent influenza virus subunit vaccine in an expanded population aged 3 years and above, enhance the post-marketing safety monitoring framework for vaccines in China, establish a long-term active surveillance mechanism, and advance the vaccine regulatory system toward higher maturity levels.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
